Tenvie Therapeutics is a biotechnology company that transforms the treatment of neurological diseases through engineered small molecules.
Tenvie Therapeutics has raised $200.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Tenvie Therapeutics's investors include ARCH Venture Partners, Mubadala Capital, F-Prime Capital.
Tenvie Therapeutics is headquartered in South San Francisco, United States.
Tenvie Therapeutics is a biotechnology company that transforms the treatment of neurological diseases through engineered small molecules.
Tenvie Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tenvie Therapeutics — Funding & Investors." VCBacked, January 8, 2025, https://www.vcbacked.co/company/tenvie-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Tenvie Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/tenvie-therapeutics
{{cite web |title=Tenvie Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tenvie-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated